drugset / Trial / NCT02773381

A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

NCT02773381

Phase 1 Completed 15 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the effect of oral semaglutide compared with placebo on postprandial glucose and triglyceride metabolism, energy intake, appetite sensations and gastric emptying in subjects with Type 2 diabetes

Timeline

Start
2016-06-02
Primary completion
2018-10-19
Completion
2018-10-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 14 mg Oral